Faeth Therapeutics (FTH) Preferred Stock Liabilities (2020)

Faeth Therapeutics (FTH) has reported Preferred Stock Liabilities for 1 consecutive years, with $61.4 million the latest figure, recorded in Q4 2020.

• For the quarter ending Q4 2020, Preferred Stock Liabilities changed N/A year-over-year to $61.4 million; the trailing twelve-month figure through Dec 2020 stood at $61.4 million (changed N/A YoY), and the FY2020 full-year result was $61.4 million, changed N/A from the prior year.
• Preferred Stock Liabilities steadied at $61.4 million in Q4 2020 per FTH's latest filing.
• Across five years, Preferred Stock Liabilities topped out at $61.4 million in Q4 2020 and bottomed at $61.4 million in Q4 2020.